---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-24-000093"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:34:27.710356+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio settles IP lawsuit with HCW, acquires TGFb trap assets and licenses

## Summary
- Settlement resolves arbitration and federal lawsuit with HCW Biologics; no monetary consideration from ImmunityBio.
- ImmunityBio receives ownership of IP and drug candidates HCW9218, HCW9219, HCW9209 for TGFb-related fusion proteins.
- HCW9218 is a bifunctional fusion protein (TGFb trap + IL-15) studied in Phase 1/1b trials for ovarian and pancreatic cancer.
- ImmunityBio also gets exclusive license to use TF Platform for oncology targets PDL-1, IL-7, IL-12, IL-18, IL-21, plus one more.
- Parties exchange mutual releases; ImmunityBio to dismiss arbitration after compliance with settlement terms.

## SEC filing metadata
- accession: 0001326110-24-000093
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611024000093/0001326110-24-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611024000093/ibrx-20240713.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-24-000093
- JSON: https://secwatch.observer/filing/0001326110-24-000093.json
- Plain text: https://secwatch.observer/filing/0001326110-24-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.